Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
Cancers
Hong, Lingzhi L; Lewis, Whitney E WE; Nilsson, Monique M; Patel, Sonia S; Varghese, Susan S; Rivera, Melvin J MJ; Du, Robyn R RR; Chen, Pingjun P; Kemp, Haley N HN; Rinsurongkawong, Waree W; Heeke, Simon S; Spelman, Amy R AR; Elamin, Yasir Y YY; Negrao, Marcelo V MV; Sepesi, Boris B; Gibbons, Don L DL; Lee, J Jack JJ; Wu, Jia J; Vokes, Natalie I NI; Heymach, John V JV; Zhang, Jianjun J; Le, Xiuning X
Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Osimertinib.
Tuberculosis And Respiratory Diseases
Park, Ji Young JY; Jang, Seung Hun SH; Lee, Chang Youl CY; Kim, Taehee T; Chung, Soo Jie SJ; Lee, Ye Jin YJ; Kim, Hwan Il HI; Kim, Joo-Hee JH; Park, Sunghoon S; Hwang, Yong Il YI; Jung, Ki-Suck KS
Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients.
Springerplus
Romero-Ventosa, Elena Yaiza EY; Blanco-Prieto, Sonia S; González-Piñeiro, Ana Lourdes AL; Rodríguez-Berrocal, Francisco Javier FJ; Piñeiro-Corrales, Guadalupe G; Páez de la Cadena, María M